RETRACTED ARTICLE: Flot2 targeted by miR-449 acts as a prognostic biomarker in glioma

Huang, Shaosong; Zheng, Shaoling; Huang, Simin; Cheng, Hui; Wen, Yuxing; Lin, Wei

doi:10.1080/21691401.2018.1549062

Cited by 13 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies found that miR-485 and miR-133 could target flotillin-2, resulting in inhibition of metastasis or epithelial-mesenchymal transition (EMT) in lung adenocarcinoma (18,19). Furthermore, flotillin-2 was targeted by miR-449 in glioma (20). In addition, miR-802 and miR-34a have also been reported to target flotillin-2 in prostate cancer and melanoma respectively (21,22).…”

Section: Discussionmentioning

confidence: 99%

Flotillin‑2 predicts poor prognosis and promotes tumor invasion in intrahepatic cholangiocarcinoma

Wang

Song

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant neoplasm arising from the intrahepatic bile ducts. As a scaffold protein of lipid rafts, flotillin-2 is upregulated in several types of cancer and promotes tumor progression and metastasis. To the best of our knowledge, the present study was the first to detect the upregulation of flotillin-2 in iCCA tissues compared with matched adjacent non-tumor tissues. In addition, immunohistochemistry was used to investigate the expression of flotillin-2 in a microarray consisting of 92 iCCA tissues. A total of 59 samples (64.1%) exhibited high flotillin-2 expression, which was significantly related to lymph node metastasis (P=0.029) and tumor-node-metastasis stage (P=0.016). Further in vitro study demonstrated that knockdown of flotillin-2 inhibited the invasive capability of iCCA cell lines, further supporting the participation of flotillin-2 in cancer invasion and metastasis. Moreover, Kaplan-Meier analysis showed patients with high flotillin-2 expression had worse overall survival outcomes. The multivariate Cox proportional hazards model further revealed that high flotillin-2 expression was an independent indicator (P=0.005) of poor prognosis for patients with iCCA. Collectively, the present study revealed that as a promoter of invasion and an independent marker of poor prognosis, flotillin-2 may serve as a potential target for the development of novel therapeutic agents for iCCA.

show abstract

Section: Discussionmentioning

confidence: 99%

Flotillin‑2 predicts poor prognosis and promotes tumor invasion in intrahepatic cholangiocarcinoma

Wang

Song

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Recently, certain aberrantly expressed miRNAs have been identified in glioma that serve crucial roles in tumor progression. For instance, downregulation of miR-449 was detected in glioma tissues and demonstrated to be involved in the tumor progression by targeting flotillin 2, which was associated with poor prognosis in patients with glioma (10). Upregulation of miR-6807-3p was observed in glioma specimens; miR-6807-3p promoted tumor progression and suppressed apoptosis by targeting dachshund family transcription factor 1 (11).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‑769‑3p inhibits tumor progression in glioma by suppressing ZEB2 and inhibiting the Wnt/β‑catenin signaling pathway

Wang¹,

Yang

Gao³

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

Accumulating evidence suggests the crucial role of microRNAs (miRNAs) in human cancers. The present study aimed to investigate the clinical and functional roles of miR-769-3p in glioma, as well as the underlying molecular mechanisms. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to determine the expression levels of miR-769-3p in glioma tissues and cells. Receiver operating characteristic (ROC) curve analysis was applied to calculate the diagnostic value of miR-769-3p. The 5-year survival rate of patients was calculated using Kaplan-Meier analysis and Cox regression analysis. Cell experiments were used to investigate the functional role of miR-769-3p in glioma. The gene target of miR-769-3p was predicted by TargetScan. Changes in the levels of Wnt signaling-related proteins were measured by western blotting. miR-769-3p was significantly downregulated in glioma tissues and serum, as well as in glioma cell lines (P<0.001). miR-769-3p expression was significantly associated with the World Health Organization grade and Karnofsky performance score. The ROC curves demonstrated that serum miR-769-3p level reliably distinguished patients with glioma from healthy individuals. High tissue miR-769-3p expression predicted poor overall survival in patients with glioma (log-rank P=0.001) and was identified as an independent prognostic factor. In addition, zinc finger E-box binding homeobox 2 (ZEB2) was demonstrated to be a direct target of miR-769-3p in glioma cells using a luciferase assay. miR-769-3p upregulation suppressed the activity of the Wnt/β-catenin signaling pathway in glioma cells. In conclusion, miR-769-3p may serve as a diagnostic and prognostic biomarker in patients with glioma and target ZEB2 to inhibit tumor progression via the Wnt/β-catenin signaling pathway. miR-769-3p may be a novel therapeutic target for the treatment of glioma.

show abstract

“…It is well acknowledged that miRNAs play pivotal roles in the physiological and pathological processes of multiple cancers, such as hepatocellular carcinoma, nasopharyngeal carcinoma, glioma, and GC [ 26 , 27 , 28 ]. As an oncogene or tumor suppressor, miRNA is involved in tumorigenesis by gene expression modulation at the posttranscriptional level [ 29 , 30 , 31 ]. Recently, the aberrant expression of miR-299-3p was identified to be associated with malignant clinicopathological characteristics and poor prognosis [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

miR-299-3p suppresses cell progression and induces apoptosis by downregulating PAX3 in gastric cancer

et al. 2021

View full text Add to dashboard Cite

Gastric cancer (GC) is ranked the fourth leading cause of cancer-related death, with an over 75% mortality rate worldwide. In recent years, miR-299-3p has been identified as a biomarker in multiple cancers, such as acute promyelocytic leukemia, thyroid cancer, and lung cancer. However, the regulatory mechanism of miR-299-3p in GC cell progression is still largely unclear. Cell viability and apoptosis tests were performed by CCK8 and flow cytometry assay, respectively. Transwell assay was recruited to examine cell invasion ability. The interaction between miR-299-3p and PAX3 was determined by the luciferase reporter system. PAX3 protein level was evaluated by western blot assay. The expression of miR-299-3p was downregulated in GC tissues and cell lines (MKN-45, AGS, and MGC-803) compared with the normal tissues and cells. Besides, overexpression of miR-299-3p significantly suppressed proliferation and invasion and promoted apoptosis in GC. Next, we clarified that PAX3 expression was regulated by miR-299-3p using a luciferase reporter system, qRT-PCR, and western blot assay. Additionally, downregulation of PAX3 repressed GC cell progression. The rescue experiments indicated that restoration of PAX3 inversed miR-299-3p-mediated inhibition on cell proliferation and invasion. miR-299-3p suppresses cell proliferation and invasion as well as induces apoptosis by regulating PAX3 expression in GC, representing desirable biomarkers for GC diagnosis and therapy.

show abstract

RETRACTED ARTICLE: Flot2 targeted by miR-449 acts as a prognostic biomarker in glioma

Cited by 13 publications

References 32 publications

Flotillin‑2 predicts poor prognosis and promotes tumor invasion in intrahepatic cholangiocarcinoma

Flotillin‑2 predicts poor prognosis and promotes tumor invasion in intrahepatic cholangiocarcinoma

MicroRNA‑769‑3p inhibits tumor progression in glioma by suppressing ZEB2 and inhibiting the Wnt/β‑catenin signaling pathway

miR-299-3p suppresses cell progression and induces apoptosis by downregulating PAX3 in gastric cancer

Contact Info

Product

Resources

About